133 related articles for article (PubMed ID: 14716343)
1. Autologous del(20q)-positive erythroid progenitor cells, re-emerging after DLI treatment of an MDS patient relapsing after allo-SCT, can provide a normal peripheral red blood cell count.
Dykes JH; Lindmark A; Lenhoff S; Winqvist I; Johansson B; Olofsson T; Olsson ML
Bone Marrow Transplant; 2004 Mar; 33(5):559-63. PubMed ID: 14716343
[TBL] [Abstract][Full Text] [Related]
2. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation.
Musso M; Porretto F; Crescimanno A; Polizzi V; Scalone R
Bone Marrow Transplant; 2004 Apr; 33(7):769-71. PubMed ID: 14755320
[TBL] [Abstract][Full Text] [Related]
3. Haemopoietic reconstitution by donor-derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation.
Mielcarek M; Bryant E; Loken M; Torok-Storb B; Storb R
Br J Haematol; 1999 May; 105(2):361-5. PubMed ID: 10233404
[TBL] [Abstract][Full Text] [Related]
4. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
6. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
8. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
Depil S; Deconinck E; Milpied N; Sutton L; Witz F; Jouet JP; Damaj G; Yakoub-Agha I;
Bone Marrow Transplant; 2004 Mar; 33(5):531-4. PubMed ID: 14716345
[TBL] [Abstract][Full Text] [Related]
9. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review.
Komrokji R; Ifthikharuddin JJ; Felgar RE; Abboud CN; Wedow LA; Connaughton A; Bennett JM
Am J Hematol; 2004 Aug; 76(4):389-94. PubMed ID: 15282676
[TBL] [Abstract][Full Text] [Related]
10. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
[TBL] [Abstract][Full Text] [Related]
11. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
12. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
15. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T; Suciu S; Brand R; Muus P; Kröger N
Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
[TBL] [Abstract][Full Text] [Related]
17. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
[TBL] [Abstract][Full Text] [Related]
18. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
20. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
